PODD Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 6.22% compared to Insulet's net margin of 14.45%. Insulet's return on equity of 36.9% beat Boston Scientific's return on equity of 9.57%.

Insulet has a consensus price target of $328.73, signalling upside risk potential of 2.29%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.93%. Given that Boston Scientific has higher upside potential than Insulet, analysts believe Boston Scientific is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Insulet's net income of $35.4M is lower than Boston Scientific's net income of $674M. Notably, Insulet's price-to-earnings ratio is 57.80x while Boston Scientific's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.81x versus 8.86x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of 6.22% compared to Insulet's net margin of -19.35%. Insulet's return on equity of 36.9% beat iRhythm Technologies's return on equity of -112.03%.

Insulet has a consensus price target of $328.73, signalling upside risk potential of 2.29%. On the other hand iRhythm Technologies has an analysts' consensus of $140.42 which suggests that it could fall by -1.59%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Insulet's net income of $35.4M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Insulet's price-to-earnings ratio is 57.80x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.81x versus 7.23x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 6.22% compared to Insulet's net margin of 30.99%. Insulet's return on equity of 36.9% beat Intuitive Surgical's return on equity of 15.82%.

Insulet has a consensus price target of $328.73, signalling upside risk potential of 2.29%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 6.72%. Given that Intuitive Surgical has higher upside potential than Insulet, analysts believe Intuitive Surgical is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Insulet's net income of $35.4M is lower than Intuitive Surgical's net income of $698.4M. Notably, Insulet's price-to-earnings ratio is 57.80x while Intuitive Surgical's PE ratio is 79.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.81x versus 22.47x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 6.22% compared to Insulet's net margin of -45.89%. Insulet's return on equity of 36.9% beat Masimo's return on equity of -39.91%.

Insulet has a consensus price target of $328.73, signalling upside risk potential of 2.29%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 21.28%. Given that Masimo has higher upside potential than Insulet, analysts believe Masimo is more attractive than Insulet.

Insulet has a beta of 1.263, which suggesting that the stock is 26.336% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than Masimo quarterly revenues of $372M. Insulet's net income of $35.4M is higher than Masimo's net income of -$170.7M. Notably, Insulet's price-to-earnings ratio is 57.80x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.81x versus 4.13x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.